$X4 Pharmaceuticals (XFOR.US)$ ⭕ As of the mid-term analysis...

$X4 Pharmaceuticals(XFOR.US)$ ⭕ As of the mid-term analysis data cutoff date, among the 23 participants in the study, Mavorisafil was generally well tolerated as a monotherapy and used in combination with G-CSF, and no serious drug-related adverse events were reported. Of the 23 participants, 3 were suspended due to unserious adverse events. ⛔ 3 ÷ 23 = 13%, 13% adverse reaction rate! 🔺 Adverse reactions leading to the discontinuation of clinical trials! ⛔ According to the current rate of burning money, the company's cash can only be maintained until the end of this year or the beginning of next year. Shares will inevitably be split and merged in reverse during the year, and additional shares will inevitably be issued. If there is no increase before the next quarterly report, the company's net assets will be negative. ❌ Pre-set reminder target price of 0.35